Emily K. Bergsland

MD

Director, Center for Neuroendocrine Tumors
Gastrointestinal oncologist

Dr. Emily Bergsland is a gastrointestinal oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center and the director of the UCSF Center for Neuroendocrine Tumors. She specializes in the multidisciplinary care of patients with neuroendocrine cancers.

Bergsland's research is focused on better understanding why neuroendocrine tumors develop, identifying and testing new therapies, and improving outcomes in affected patients.

Bergsland earned her medical degree at the University of Minnesota, then completed a residency in internal medicine and fellowship in medical oncology at UCSF.

  • Education

    University of Minnesota, 1989

  • Residencies

    UCSF, Internal Medicine, 1992

  • Fellowships

    UCSF, Medical Oncology, 1995

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

Conditions I specialize in

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    236 Ratings
    Explained things in a way that was easy to understand
    236 Ratings
    Did the doctor pay attention to your concerns
    236 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    232 Ratings
    Knew the important information about your medical history
    235 Ratings
    The provider showed respect for what you had to say
    233 Ratings
    The provider spent enough time with me
    234 Ratings
    Read all reviews About our process

    Selected research

    Decorative Caduceus

    Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0...

    Recruiting

    Decorative Caduceus

    Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronc...

    Will be compared between patients with a bronchial neuroendocrine tumor (NET) receiving lutetium Lu 177 dotatate to those receiving everolimus. The distribution of PFS will be estimated using the Kaplan Meier method. Will be teste...

    Recruiting

    Contact me

    Providers on my team

    Share